Menu

PBL Assay Science announces a licensing agreement with HumanZyme, Inc

23-02-2015

PBL Assay Science announces a licensing agreement with HumanZyme, Inc. (Chicago, USA) to expand reagent offerings. The agreement allows PBL to provide ~50 authentic human cell-expressed (HCE) cytokines and growth factors directly to scientists worldwide. HumanZyme, Inc. is a global leader in providing highly authentic recombinant proteins from human cells under the HumanKine® brand and a preferred outsourcing supplier of human protein production. These human cell-expressed proteins mimic native human proteins more closely than proteins from non-human expression systems, such as E. coli, in terms of glycosylation, assembly, location, and structure. PBL Assay Science is a major provider of products, assay services, and information related to interferons, cytokines, antibodies, ELISAs, and assay science. The company employs state-of-the-art technology and years of know-how in conducting assay services and manufacturing world-class products for scientists around the globe. "HumanZyme's leadership and innovations in authentic human proteins provide a perfect complement to our unique cytokine and interferon reagents, ELISA, and assay service offerings," said Robert Pestka, CEO, PBL Assay Science. "Introducing these proteins to our product line enhances our ability to help scientists approach their experiments using more biologically relevant research tools." "For over twenty years, PBL has grown not only in number of products offered but in knowledge around interferons, cytokines and assay science," said Sean Doctor, Executive Vice President and GM, HumanZyme, Inc. "Combining our human cell-expressed reagents with PBL's expertise expands both companies' capability to address researchers' most difficult problems." The agreement between PBL Assay Science and HumanZyme, Inc. begins this month. Human cell-expressed (HCE) proteins in the agreement include members of the human TGF beta, Fibroblast Growth Factor (FGF), Hematopoietin and Interleukin, and Tyrosine Kinase Receptor Signaling families, and TNF-alpha.
ENQUIRY FORM

More News

  • Stratech Scientific Seminar Series - 18.02.2015

  • Testimonial - Dr. Andrew Brooks, PHD Associate Professor and COO of RUCDR Infinite Biologics.

  • Irish Association for Cancer Research 2015 Meeting

  • Testimonial - Mina Kalantari, Ph.D., Assistant Researcher, University of California, Irvine